Novartis News | finanzen.ch

Novartis Aktie VALOR 1200526 / ISIN CH0012005267

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

08.12.21	New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer (GlobeNewswire)
02.12.21	Novartis R&D day spotlights attractive growth profile, underpinned by strong in-market brands, 20 potential high value pipeline assets, and technology platforms (GlobeNewswire)
04.11.21	New data at ASH spotlight Novartis recently approved Scemblix®, next-generation CAR-T platform and expanding hematology portfolio (GlobeNewswire)
04.11.21	Novartis to sell its Roche stake in a bilateral transaction to Roche (GlobeNewswire)
04.11.21	Novartis verkauft ihre Roche-Beteiligung in einer bilateralen Transaktion an Roche (GlobeNewswire)
29.10.21	FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia (GlobeNewswire)
26.10.21	Novartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of Sandoz (GlobeNewswire)
26.10.21	Novartis erzielt im dritten Quartal solide Ergebnisse – mit starkem Wachstum bei Innovative Medicines. Das Unternehmen kündigt eine strategische Überprüfung von Sandoz an (GlobeNewswire)
25.10.21	Novartis top-line results for CANOPY-1 Phase III study support further evaluation of canakinumab in lung cancer (GlobeNewswire)
19.10.21	Global Heart Hub and Novartis partner to tackle ASCVD, a global health crisis and world’s #1 killer (GlobeNewswire)
11.10.21	Sandoz completes acquisition of GSK’s cephalosporin business, reinforcing leading global position in antibiotics (GlobeNewswire)
01.10.21	Sandoz Resolves Legacy Federal Government Civil Investigation in the U.S. Regarding Generic Drugs (GlobeNewswire)
30.09.21	Novartis accelerates efforts toward ESG targets to increase access to medicines, improve health equity and achieve net-zero carbon emissions (GlobeNewswire)
19.09.21	Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer (GlobeNewswire)
17.09.21	Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS) (GlobeNewswire)
17.09.21	Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021 (GlobeNewswire)
08.09.21	Sandoz strengthens pipeline by entering into agreement for biosimilar bevacizumab, a key oncology medicine (GlobeNewswire)
30.08.21	Novartis presents important overall survival and quality-of-life results across solid tumor portfolio, among other key data at ESMO (GlobeNewswire)
24.08.21	Novartis provides update on BELINDA study investigating Kymriah® as second-line treatment in aggressive B-cell non-Hodgkin lymphoma (GlobeNewswire)
03.08.21	Novartis announces lift of partial clinical trial hold and plans to initiate a new, pivotal Phase 3 study of intrathecal OAV-101 in older patients with SMA (GlobeNewswire)
21.07.21	Novartis hat im zweiten Quartal dank der Dynamik wichtiger Wachstums-marken eine starke Performance erzielt; Prognose für 2021 unverändert (GlobeNewswire)
21.07.21	Novartis delivered strong Q2 performance, driven by momentum of key growth brands. FY 2021 guidance unchanged. (GlobeNewswire)
20.07.21	Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable (GlobeNewswire)
28.06.21	Novartis appoints Rob Kowalski as Chief People & Organization Officer (GlobeNewswire)
18.06.21	New Zolgensma data demonstrate age-appropriate development when used presymptomatically and rapid, clinically meaningful efficacy in symptomatic children, even those with severe SMA at baseline (GlobeNewswire)
11.06.21	Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria (GlobeNewswire)
06.06.21	Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN) (GlobeNewswire)
04.06.21	Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC (GlobeNewswire)
04.06.21	Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy (GlobeNewswire)
03.06.21	Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera (GlobeNewswire)
03.06.21	Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study (GlobeNewswire)
02.06.21	Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma (GlobeNewswire)
02.06.21	Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients (GlobeNewswire)
02.06.21	Novartis presents positive Phase III results from JUNIPERA study supporting Cosentyx® as a potential treatment in a JIA population at EULAR 2021 (GlobeNewswire)
01.06.21	Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis (GlobeNewswire)
28.05.21	Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program (GlobeNewswire)
27.05.21	Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19 (GlobeNewswire)
19.05.21	Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer (GlobeNewswire)
18.05.21	Sandoz announces plans to further strengthen its antibiotics manufacturing setup in Europe (GlobeNewswire)
17.05.21	US Supreme Court denies Sandoz petition to review biosimilar Erelzi® (etanercept-szzs) case (GlobeNewswire)
03.05.21	Sandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine (GlobeNewswire)
01.05.21	Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept (GlobeNewswire)
27.04.21	Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed. (GlobeNewswire)
27.04.21	Wichtige Wachstumstreiber und Neueinführungen von Novartis setzen ihre Dynamik im ersten Quartal fort und erhalten das Vertrauen in das Wachstum; Konzernprognose für 2021 bestätigt (GlobeNewswire)
30.03.21	Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP) (GlobeNewswire)
23.03.21	Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer (GlobeNewswire)
22.03.21	Novartis appoints Karen Hale as Chief Legal Officer (GlobeNewswire)
15.03.21	New Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post-treatment (GlobeNewswire)
09.03.21	Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer (GlobeNewswire)
05.03.21	Novartis announces change to the Executive Committee (GlobeNewswire)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Givaudan	3’833.00	0.87 %	K V
Nestle	90.24	0.78 %	K V
Roche Hldg G	296.70	0.78 %	K V
Sonova Hldg	262.80	0.42 %	K V
Kuehne+Nagel Int	206.70	0.39 %	K V
Part Grp Hldg	1’291.50	-1.45 %	K V
Logitech Intl	77.34	-1.65 %	K V
Geberit	558.20	-1.86 %	K V
ABB	46.96	-2.69 %	K V
Swisscom	513.00	-3.93 %	K V

mehr

28.03.25		Angespannte Stimmung in New York: Dow Jones fällt letztendlich
28.03.25		Freitagshandel in New York: S&P 500 gibt nachmittags nach
28.03.25		Angespannte Stimmung in New York: Dow Jones gibt nachmittags nach
28.03.25		Novartis-Aktie: FDA erteilt erweiterte Zulassung für Krebsmedikament
28.03.25		Zurückhaltung in New York: Dow Jones präsentiert sich am Mittag schwächer